CA2675366A1 - Polymorphismes geniques predictifs d'une bitherapie a base de tki - Google Patents
Polymorphismes geniques predictifs d'une bitherapie a base de tki Download PDFInfo
- Publication number
- CA2675366A1 CA2675366A1 CA002675366A CA2675366A CA2675366A1 CA 2675366 A1 CA2675366 A1 CA 2675366A1 CA 002675366 A CA002675366 A CA 002675366A CA 2675366 A CA2675366 A CA 2675366A CA 2675366 A1 CA2675366 A1 CA 2675366A1
- Authority
- CA
- Canada
- Prior art keywords
- cancer
- antibody
- patient
- snp
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US88562007P | 2007-01-18 | 2007-01-18 | |
| US60/885,620 | 2007-01-18 | ||
| PCT/US2008/000661 WO2008088861A2 (fr) | 2007-01-18 | 2008-01-17 | Polymorphismes géniques prédictifs d'une bithérapie à base de tki |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2675366A1 true CA2675366A1 (fr) | 2008-07-24 |
Family
ID=39636587
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002675366A Abandoned CA2675366A1 (fr) | 2007-01-18 | 2008-01-17 | Polymorphismes geniques predictifs d'une bitherapie a base de tki |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US8435752B2 (fr) |
| EP (1) | EP2126117A2 (fr) |
| AU (1) | AU2008205457A1 (fr) |
| CA (1) | CA2675366A1 (fr) |
| WO (1) | WO2008088861A2 (fr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004011625A2 (fr) | 2002-07-31 | 2004-02-05 | University Of Southern California | Polymorphismes de prediction de maladies et resultat therapeutique |
| CA2643053A1 (fr) | 2006-03-03 | 2007-09-13 | University Of Southern California | Polymorphismes dans la sous-unite alpha-1 du canal sodique sensible a la tension convenant comme marqueurs pour le choix de therapie |
| CA2675362A1 (fr) | 2007-01-18 | 2008-07-24 | University Of Southern California | Polymorphismes dans la voie de signalisation de l'egfr en tant que marqueurs pour le traitement du cancer |
| CA2675366A1 (fr) | 2007-01-18 | 2008-07-24 | University Of Southern California | Polymorphismes geniques predictifs d'une bitherapie a base de tki |
| EP2126112A2 (fr) | 2007-01-18 | 2009-12-02 | University Of Southern California USC Stevens | Polymorphismes géniques en tant que prédicteurs de progression tumorale et leur utilisation en cancérothérapie |
| EP3620154A1 (fr) | 2009-02-06 | 2020-03-11 | University Of Southern California | Compositions thérapeutiques comprenant des monoterpènes |
| US8568968B2 (en) | 2009-04-13 | 2013-10-29 | University Of Southern California | EGFR polymorphisms predict gender-related treatment |
| WO2010124239A2 (fr) * | 2009-04-24 | 2010-10-28 | University Of Southern California | Polymorphismes génétiques associés à des résultats cliniques d'un traitement anticancéreux par des inhibiteurs des topoisomérases |
| IL299365A (en) | 2010-05-27 | 2023-02-01 | Genmab As | Monoclonal antibodies against 2HER |
| NZ604007A (en) | 2010-05-27 | 2015-03-27 | Genmab As | Monoclonal antibodies against her2 epitope |
| WO2012143524A2 (fr) | 2011-04-20 | 2012-10-26 | Genmab A/S | Anticorps bispécifiques contre her2 et cd3 |
| BR112014019034A8 (pt) * | 2012-01-31 | 2017-07-11 | Smithkline Beecham Cork Ltd | Método para tratamento de câncer |
| WO2013118073A1 (fr) * | 2012-02-07 | 2013-08-15 | Bioalternatives Sas | Serpinb4, comme marqueur destiné à une évaluation précoce de la réponse à des thérapies anti-egfr par un procédé non invasif |
| US11015190B2 (en) * | 2013-09-17 | 2021-05-25 | Lucence Life Sciences Pte Ltd | Method of treating a patient having renal cancer |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8311018D0 (en) | 1983-04-22 | 1983-05-25 | Amersham Int Plc | Detecting mutations in dna |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US6492107B1 (en) | 1986-11-20 | 2002-12-10 | Stuart Kauffman | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
| DE3587814T2 (de) | 1985-03-30 | 1994-11-10 | Marc Ballivet | Verfahren zum erhalten von dns, rns, peptiden, polypeptiden oder proteinen durch dns-rekombinant-verfahren. |
| US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US4998617A (en) | 1986-09-15 | 1991-03-12 | Laura Lupton Inc | Facial cosmetic liquid make up kit |
| EP0279582A3 (fr) | 1987-02-17 | 1989-10-18 | Pharming B.V. | Séquences d'ADN pour diriger des protéines vers les glandes mammaires afin d'être sécrétées efficacement |
| US5202231A (en) | 1987-04-01 | 1993-04-13 | Drmanac Radoje T | Method of sequencing of genomes by hybridization of oligonucleotide probes |
| US6270961B1 (en) | 1987-04-01 | 2001-08-07 | Hyseq, Inc. | Methods and apparatus for DNA sequencing and DNA identification |
| US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
| US5176996A (en) | 1988-12-20 | 1993-01-05 | Baylor College Of Medicine | Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5256775A (en) | 1989-06-05 | 1993-10-26 | Gilead Sciences, Inc. | Exonuclease-resistant oligonucleotides |
| US5264564A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences | Oligonucleotide analogs with novel linkages |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| CA2090126C (fr) | 1990-08-02 | 2002-10-22 | John W. Schrader | Methodes de production de proteines dotees d'une fonction desiree |
| US5210015A (en) | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
| WO1993011794A1 (fr) | 1991-12-13 | 1993-06-24 | Xoma Corporation | Procedes et matieres de preparation de domaines variables d'anticorps modifies et leurs utilisations therapeutiques |
| JP2775346B2 (ja) | 1992-04-03 | 1998-07-16 | アプライド バイオシステムズ，インコーポレイテッド | プローブ構成物および方法 |
| US5605798A (en) | 1993-01-07 | 1997-02-25 | Sequenom, Inc. | DNA diagnostic based on mass spectrometry |
| ATE267877T1 (de) | 1993-01-07 | 2004-06-15 | Sequenom Inc | Dns - sequenzierung durch massenspektronomie |
| US5858659A (en) | 1995-11-29 | 1999-01-12 | Affymetrix, Inc. | Polymorphism detection |
| US5952172A (en) | 1993-12-10 | 1999-09-14 | California Institute Of Technology | Nucleic acid mediated electron transfer |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US5571676A (en) | 1995-06-07 | 1996-11-05 | Ig Laboratories, Inc. | Method for mismatch-directed in vitro DNA sequencing |
| US5968740A (en) | 1995-07-24 | 1999-10-19 | Affymetrix, Inc. | Method of Identifying a Base in a Nucleic Acid |
| US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
| CA2303206A1 (fr) | 1997-09-10 | 1999-03-18 | University Of Maryland, Baltimore | Procede d'amplification d'adn et de produits de clivage de mesappariement d'arn |
| JP4334141B2 (ja) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作 |
| AU1728800A (en) | 1998-11-18 | 2000-06-05 | Genentech Inc. | Antibody variants with higher binding affinity compared to parent antibodies |
| WO2001036686A2 (fr) | 1999-11-15 | 2001-05-25 | University Of Southern California | Prediction de reponse therapeutique d'apres le polymorphisme genomique |
| US6716581B2 (en) | 2000-03-31 | 2004-04-06 | University Of Southern California | Manganese superoxide dismutase gene polymorphism for predicting cancer susceptibility |
| US20060160074A1 (en) | 2001-12-27 | 2006-07-20 | Third Wave Technologies, Inc. | Pharmacogenetic DME detection assay methods and kits |
| AU2003235470A1 (en) | 2002-06-19 | 2004-01-06 | Smithkline Beecham Corporation | Predictive markers in cancer therapy |
| DE10228103A1 (de) | 2002-06-24 | 2004-01-15 | Bayer Cropscience Ag | Fungizide Wirkstoffkombinationen |
| WO2004011625A2 (fr) | 2002-07-31 | 2004-02-05 | University Of Southern California | Polymorphismes de prediction de maladies et resultat therapeutique |
| US7563748B2 (en) | 2003-06-23 | 2009-07-21 | Cognis Ip Management Gmbh | Alcohol alkoxylate carriers for pesticide active ingredients |
| EP1664716A4 (fr) * | 2003-08-15 | 2008-08-13 | Smithkline Beecham Corp | Biomarqueurs contre le cancer |
| MXPA06013952A (es) | 2004-06-04 | 2007-02-08 | Smithkline Beecham Cork Ltd | Metodo para el tratamiento de cancer. |
| US7794960B2 (en) | 2004-06-04 | 2010-09-14 | Glaxosmithkline Llc | Predictive biomarkers in cancer therapy |
| EP1769092A4 (fr) | 2004-06-29 | 2008-08-06 | Europ Nickel Plc | Lixiviation amelioree de metaux de base |
| AU2005267148A1 (en) * | 2004-07-01 | 2006-02-02 | University Of Southern California | Genetic markers for predicting disease and treatment outcome |
| GB0427131D0 (en) | 2004-12-10 | 2005-01-12 | Glaxosmithkline Biolog Sa | Novel combination |
| US7862995B2 (en) * | 2004-12-10 | 2011-01-04 | Targeted Molecular Diagnostics | Methods and materials for predicting responsiveness to treatment with dual tyrosine kinase inhibitor |
| ATE498358T1 (de) | 2005-06-29 | 2011-03-15 | Compumedics Ltd | Sensoranordnung mit leitfähiger brücke |
| US20090181016A1 (en) | 2005-11-30 | 2009-07-16 | University Of Southern California | FCgamma POLYMORPHISMS FOR PREDICTING DISEASE AND TREATMENT OUTCOME |
| CA2643053A1 (fr) | 2006-03-03 | 2007-09-13 | University Of Southern California | Polymorphismes dans la sous-unite alpha-1 du canal sodique sensible a la tension convenant comme marqueurs pour le choix de therapie |
| CA2644517A1 (fr) | 2006-03-03 | 2007-09-13 | University Of Southern California | Marqueurs genetiques permettant de predire une affection et l'issue d'un traitement |
| US7807364B2 (en) | 2006-03-03 | 2010-10-05 | University Of Southern California | Angiogenesis pathway gene polymorphisms for therapy selection |
| TW200801513A (en) | 2006-06-29 | 2008-01-01 | Fermiscan Australia Pty Ltd | Improved process |
| CA2675366A1 (fr) | 2007-01-18 | 2008-07-24 | University Of Southern California | Polymorphismes geniques predictifs d'une bitherapie a base de tki |
| EP2126112A2 (fr) | 2007-01-18 | 2009-12-02 | University Of Southern California USC Stevens | Polymorphismes géniques en tant que prédicteurs de progression tumorale et leur utilisation en cancérothérapie |
| CA2675362A1 (fr) | 2007-01-18 | 2008-07-24 | University Of Southern California | Polymorphismes dans la voie de signalisation de l'egfr en tant que marqueurs pour le traitement du cancer |
| AU2008206051A1 (en) | 2007-01-18 | 2008-07-24 | University Of Southern California | Gene polymorphisms as sex-specific predictors in cancer therapy |
| WO2008088893A2 (fr) | 2007-01-18 | 2008-07-24 | University Of Southern California | Polymorphismes génétiques dans le vegf et le récepteur 2 du vegf en tant que marqueurs pour une thérapie contre le cancer |
| EP2109686A2 (fr) | 2007-01-18 | 2009-10-21 | University Of Southern California | Marqueurs genetiques pour la prediction de sensibilite a une polytherapie |
| WO2009140556A2 (fr) | 2008-05-15 | 2009-11-19 | University Of Southern California | Analyse du génotype et de l'expression permettant de prédire l'évolution d'une maladie et de choisir la thérapie la plus adaptée |
| WO2010000020A1 (fr) | 2008-06-30 | 2010-01-07 | Cathrx Ltd | Cathéter |
| US20120108441A1 (en) | 2009-04-24 | 2012-05-03 | University Of Southern California | Polymorphisms in angiogenesis pathway genes associated with tumor recurrence in surgery treated cancer patients |
| US20120100134A1 (en) | 2009-04-24 | 2012-04-26 | University Of Southern California | Genetic variants in angiogenesis pathway associated with clinical outcome |
-
2008
- 2008-01-17 CA CA002675366A patent/CA2675366A1/fr not_active Abandoned
- 2008-01-17 AU AU2008205457A patent/AU2008205457A1/en not_active Abandoned
- 2008-01-17 WO PCT/US2008/000661 patent/WO2008088861A2/fr not_active Ceased
- 2008-01-17 US US12/523,514 patent/US8435752B2/en not_active Expired - Fee Related
- 2008-01-17 EP EP08713180A patent/EP2126117A2/fr not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008088861A2 (fr) | 2008-07-24 |
| US20100183593A1 (en) | 2010-07-22 |
| EP2126117A2 (fr) | 2009-12-02 |
| WO2008088861A3 (fr) | 2008-12-18 |
| US8435752B2 (en) | 2013-05-07 |
| AU2008205457A1 (en) | 2008-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8435752B2 (en) | Gene polymorphisms predictive for dual TKI therapy | |
| US8357369B2 (en) | Genetic markers for predicting responsiveness to combination therapy | |
| US8278061B2 (en) | Polymorphisms in the EGFR pathway as markers for cancer treatment | |
| US7807364B2 (en) | Angiogenesis pathway gene polymorphisms for therapy selection | |
| US20100104583A1 (en) | Gene Polymorphisms in VEGF and VEGF Receptor 2 as Markers for Cancer Therapy | |
| US20120094291A1 (en) | FCgamma POLYMORPHISMS FOR PREDICTING DISEASE AND TREATMENT OUTCOME | |
| EP1774039A2 (fr) | Marqueurs génétiques de prédiction de maladies et résultat thérapeutique | |
| US20100099720A1 (en) | Gene Polymorphisms as Sex-Specific Predictors in Cancer Therapy | |
| US8216781B2 (en) | Gene polymorphisms as predictors of tumor progression and their use in cancer therapy | |
| US20100152202A1 (en) | Tissue Factor Promoter Polymorphisms |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20140117 |